WEH evidence card asking whether NMN slows ageing, with an NMN bottle and hourglass; verdict uncertain.

Does NMN or NAD+ supplementation slow aging and extend lifespan?

WhatEvidence.Health Claim Check

A careful look at the human evidence behind one of longevity medicine’s most popular supplement claims.

WEH Verdict: Uncertain

NMN can raise NAD+ related markers in humans, but no human trial has shown that NMN or NAD+ supplementation slows aging or extends lifespan.

Claim checkedNMN/NAD+ slows aging
PopulationAdults
Evidence typeHuman RCTs + reviews
Last reviewed6 June 2026
Bottom Line

NMN is a plausible NAD+ booster, not a proven longevity treatment. Randomized human studies show that NMN can increase NAD+ related markers, and some trials report small improvements in muscle insulin sensitivity, walking speed, sleep, or exercise-related measures. But the central claim – that NMN or NAD+ supplementation slows human aging or extends lifespan – is not supported by direct human evidence.

The claim

“NMN, NAD+, or NAD+ booster supplements slow aging, reverse biological age, and help people live longer.”

This is a broad claim, so WEH splits it into smaller claims. Does NMN raise NAD+? Does it improve aging-related body functions? Does it lower biological age? Does it extend lifespan?

The answer changes depending on which part of the claim you ask about.

Evidence at a glance

Yes
Raises NAD+ markers
Mixed
Function and metabolism
Unclear
Biological age meaning
None
Human lifespan evidence

What is NMN?

NMN stands for nicotinamide mononucleotide. It is a molecule the body can use to make NAD+.

NAD+ stands for nicotinamide adenine dinucleotide. It helps cells turn food into energy and supports processes involved in DNA repair, stress responses, and metabolism. NAD+ biology is a real and important field of research, but a real mechanism does not prove a real lifespan benefit.

Human studies have mostly measured short-term biomarkers and functional tests. They have not measured whether people live longer.

What the evidence says – click any finding to expand

Each card separates a specific sub-claim from the larger marketing claim. This matters because “raises NAD+” and “extends lifespan” are not the same claim.

Supported
NMN increases NAD+ related markers in humans
GRADE: Moderate for biomarker change
v

Several randomized human studies report that oral NMN increases blood NAD+ or NAD+ metabolites. This is the most consistent human finding, and it supports the idea that NMN can act as a NAD+ precursor.

Mechanism: NMN is part of the body’s NAD+ salvage pathway, meaning it can be converted into NAD+ through normal cellular chemistry.
Caveat: A higher NAD+ marker is a surrogate outcome. A surrogate outcome is a marker that may point toward a biological effect, but it does not prove longer life, slower aging, or fewer age-related diseases.
Systematic review Older adult RCT Dose trial
Promising
Some studies show modest metabolic or exercise-related benefits
GRADE: Low-Moderate
v

A small randomized trial in women with overweight or obesity and prediabetes found improved muscle insulin sensitivity after 10 weeks of NMN. Another randomized trial in amateur runners found improved aerobic capacity measures during exercise training, though not all exercise outcomes improved.

Mechanism: NAD+ is involved in energy metabolism, mitochondrial function, and muscle cell signaling, so metabolic and exercise outcomes are biologically plausible.
Caveat: These are short-term, specific outcomes in selected groups. They do not prove that NMN slows aging across the whole body.
Prediabetes RCT Runner RCT
Promising
Some older-adult studies report small physical function or sleep improvements
GRADE: Low
v

Trials in older adults have reported findings such as maintained walking speed, improved lower limb function, reduced drowsiness, or improved sleep-quality scores. These findings are interesting because they involve outcomes people can feel, not just lab markers.

Mechanism: Possible pathways include improved cellular energy handling and muscle metabolism.
Caveat: Effects are generally modest, follow-up is short, and some outcomes are subjective. These trials do not show reduced disability, disease, or mortality.
Igarashi 2022 Kim 2022 Morifuji 2024
Uncertain
“Biological age” findings are not the same as proven anti-aging
GRADE: Very Low-Low
v

Some trials and product-linked studies report changes in calculated “biological age” or aging-related biomarkers. These results are hypothesis-generating, but they do not prove that a person is aging more slowly in a clinically meaningful way.

Mechanism: Biological age tools use blood tests, methylation markers, or algorithms to estimate age-related biology. These tools may be useful in research.
Caveat: A changed score does not automatically mean fewer heart attacks, less dementia, less frailty, or longer life. Many biological-age tools are still being validated.
Dose trial Systematic review
Not supported
No human evidence shows lifespan extension
GRADE: Very Low for lifespan claim
v

No randomized human trial has shown that NMN, NAD+, or related NAD+ boosters make people live longer. Human trials have generally lasted weeks or months, not years or decades.

Why this matters: Lifespan is a hard clinical outcome. To support a lifespan claim, studies would need long follow-up and outcomes such as mortality, major disease, frailty, or disability.
Caveat: Animal results and biomarker changes can justify more research. They cannot prove human lifespan extension.
Systematic review Clinical evidence review
Uncertain
Long-term safety is not well established
GRADE: Low for long-term safety
v

Short-term trials generally report good tolerability, but long-term daily use has not been studied well enough to make strong safety claims. In Australia, the TGA has set conditions for NMN-containing listed medicines, including adult-only use, oral route, a maximum recommended daily dose of 500 mg, and recommended use for 12 weeks or less.

Safety context: NMN changes NAD+ metabolism, a pathway involved in many normal cell processes. That makes long-term safety especially important to study.
Caveat: People who are pregnant, breastfeeding, have active cancer, or have complex medical conditions should not treat NMN as a proven general wellness supplement.
Safety review TGA safety alert

Are the results consistent?

The evidence is consistent for NAD+ marker changes, but not for anti-aging outcomes.

Human studies generally agree that NMN can increase NAD+ related markers. They are less consistent on physical performance, metabolism, sleep, and biological-age outcomes.

This is not surprising. The studies use different doses, populations, outcome measures, and follow-up periods. Some study healthy adults. Some study older adults. Some study people with metabolic risk. A short trial in runners cannot answer the same question as a long trial of frailty, disease, or lifespan.

Why WEH Rates It This Way
Uncertain
Biologically plausible, but not clinically proven The strongest claim, “slows aging and extends lifespan,” is not directly supported by human outcomes.
  • Human RCTs show short-term biomarker changes and some modest functional signals.
  • No human trial shows longer lifespan, lower mortality, or durable prevention of age-related disease.
  • Most studies are small, short, and focused on surrogate outcomes.
  • Animal data and mechanism are not enough to prove human anti-aging benefit.

Evidence summary table

For readers who want to inspect the main studies behind the verdict.

On mobile: swipe sideways to view all columns.
Citation / N Key result Risk of bias / limits
Wen et al. 2024
N: Multiple RCTs
 NMN increased NAD+ related markers; clinical outcomes were limited. Short trials, small samples, surrogate outcomes.
Yoshino et al. 2021
N: 25 postmenopausal women with prediabetes
 Improved muscle insulin sensitivity and insulin signaling. Small, specific population, metabolic endpoint only.
Liao et al. 2021
N: 48 amateur runners
 Improved some aerobic capacity measures with exercise training. Exercise-trained group; not an aging or lifespan study.
Igarashi et al. 2022
N: Older men
 Reported nominal improvements in gait speed and left grip test; no body-composition effect. Modest effects; authors called for larger validation.
Kim et al. 2022
N: 108 older adults
 Afternoon NMN improved lower limb function and reduced drowsiness. Short-term; functional and sleep-related outcomes.
Morifuji et al. 2024
N: Older adults
 Increased blood NAD+ levels; maintained walking speed; improved sleep-quality scores. Short-term; not powered for disease or lifespan.
Yi et al. 2023
N: 80 middle-aged healthy adults
 Reported increased blood NAD+ and changes in blood biological-age measure over 60 days. Biological age is a surrogate; short follow-up.
TGA 2025
N: Not applicable
 Set adult-only, oral-route, dose and duration conditions for NMN listed medicines in Australia. Regulatory conditions are not proof of anti-aging efficacy.
Safety note Short-term NMN use appears generally well tolerated in published human trials. Long-term daily use is much less certain. In Australia, the Therapeutic Goods Administration has specified that listed medicines containing NMN should be oral, adult-only, no more than 500 mg per day, and recommended for 12 weeks or less. People who are pregnant, breastfeeding, being treated for cancer, taking regular medicines, or managing complex health conditions should seek medical advice before using NMN.
What we still do not know We still do not know whether NMN reduces frailty, dementia, heart disease, cancer, disability, or death. We also do not know the best dose, best duration, best population, or long-term safety profile.

What this means for you

Practical takeaway

If your goal is to raise NAD+ related markers, NMN appears capable of doing that.

If your goal is to slow aging, reverse biological age, or live longer, the evidence is not there yet.

  • Treat NMN as experimental for longevity, not proven.
  • Be skeptical of lifespan, “reverse aging,” or “cellular age reset” claims.
  • Do not confuse animal data, mechanisms, or biomarker changes with demonstrated human lifespan benefit.
  • Prioritize exercise, sleep, blood pressure control, smoking avoidance, healthy diet, and social connection, which have stronger real-world evidence for healthy aging.

Sources

  1. Wen J, et al. Efficacy and safety of nicotinamide mononucleotide supplementation: a systematic review of randomized controlled trials. 2024. Study type: systematic review of RCTs. Full text
  2. Igarashi M, et al. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. NPJ Aging. 2022. Study type: randomized controlled trial. PMID: 35927255. PubMed
  3. Yi L, et al. The efficacy and safety of beta-nicotinamide mononucleotide supplementation in healthy middle-aged adults. GeroScience. 2023. Study type: randomized controlled trial. DOI: 10.1007/s11357-022-00705-1. Journal page
  4. Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. Study type: randomized controlled trial. PMID: 33888596. PubMed
  5. Liao B, et al. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. J Int Soc Sports Nutr. 2021;18:54. Study type: randomized controlled trial. PMID: 34238308. PubMed
  6. Kim M, et al. Effect of 12-week intake of nicotinamide mononucleotide on sleep quality, fatigue, and physical performance in older adults. Nutrients. 2022. Study type: randomized controlled trial. PMID: 35215405. PubMed
  7. Morifuji M, et al. Ingestion of beta-nicotinamide mononucleotide increased blood NAD+ levels and improved sleep quality in older adults. 2024. Study type: randomized controlled trial. PMID: 38789831. PubMed
  8. Freeberg KA, et al. Dietary supplementation with NAD+-boosting compounds in humans. 2023. Study type: narrative review. Full text
  9. Therapeutic Goods Administration. NAD, NAD+, NADH or NMN medicines sold in Australia. Published 7 April 2025. Study type: regulatory safety alert. TGA

WhatEvidence.Health – Last reviewed 6 June 2026

This is general health information for evidence review. It is not personal medical advice. Discuss supplements with a qualified health professional, especially if you have medical conditions or take regular medicines.

Similar Posts